← Back to Search

Contrast Agent

Contrast Enhanced Ultrasound for Pancreatic Cancer

Phase 1
Recruiting
Led By Srinivas Gaddam, MD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have unexplained pancreatitis, pancreas mass(es), or pancreatic cystic lesions or worrisome clinical, imaging or laboratory findings
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months, 6 months, 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether a new type of ultrasound that uses contrast dye provides better information about pancreatic tumors than traditional ultrasound.

Who is the study for?
This trial is for individuals who are undergoing endoscopic ultrasound due to unexplained pancreatitis, pancreatic masses, or cystic lesions. It's also open to those with concerning clinical signs, imaging results, or lab findings related to the pancreas.
What is being tested?
The study tests if using a special dye (contrast) during an endoscopic ultrasound can better evaluate pancreatic tumors and precursor lesions like cysts compared to the usual method without contrast.
What are the potential side effects?
Potential side effects may include discomfort from the procedure itself and reactions to the contrast agent used in CE-EUS such as mild allergic reactions or temporary changes in taste.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have unexplained pancreatitis or suspicious pancreatic findings.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months, 6 months, 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months, 6 months, 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The results obtained by EUS versus contrast EUS to diagnose pancreas cystic lesions, mass lesion, and origin of pancreatitis.
Secondary study objectives
Quantitative Parameters of Pancreas Lesions

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Contrast EUSExperimental Treatment1 Intervention
Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
513 Previous Clinical Trials
163,189 Total Patients Enrolled
11 Trials studying Pancreatitis
2,120 Patients Enrolled for Pancreatitis
Srinivas Gaddam, MDPrincipal Investigator - Cedars-Sinai Medical Center
Cedars-Sinai Medical Center, Sound Physicians Platinum Group Pc
Kurnool Medical College (Medical School)
St Johns Mercy Medical Center (Residency)
~34 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top